$ATXS News
Last published 9mo ago
- 9mo agoATXSAstria Stockholders Vote to Approve Acquisition by BioCrystBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS) today announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve the acquisition of Astria by BioCryst
- 1y agoATXSAstria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of NavenibartBusiness Wire-- Final ALPHA-STAR Phase 1b/2 Results from the Full-Enrollment Population (n=29) Remain Highly Consistent with Prior Results from the Target-Enrollment Population (n=16), Demonstrating Strong Efficacy, Favorable
- 1y agoATXSAstria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific MeetingBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final results from the
- 1y agoATXSBCRXBioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth ProfileGlobeNewswire– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the
- 1y agoATXSBCRXBioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth ProfileBusiness Wire– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the
- 1y agoATXSAstria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific MeetingBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present two posters at the Canadian
- 1y agoATXSAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 173,000 shares of Astria's
- 1y agoATXSAstria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT TrialBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it has begun opening clinical trial sites in
- 1y agoATXSAstria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and VenereologyBusiness Wire-- Results Support Potential for STAR-0310 to be Best-in-Class OX40 Antagonist -- -- STAR-0310 Exhibits Longest-in-Class Half-Life of 68 Days and Cytokine Suppression Lasting At Least 20 Weeks After a Single 300 mg SC
- 1y agoATXSAstria Therapeutics, Inc. (ATXS) Presents at Cantor Global Healthcare Conference 2025 TranscriptEarnings Call Transcripts
- 1y agoATXSAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 128,000 shares of Astria's
- 1y agoATXSAstria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025Business WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial data from the Phase
- 1y agoATXSAstria Therapeutics to Present at Upcoming Cantor Global Healthcare ConferenceBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive
- 1y agoATXSAstria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateBusiness Wire-- Kaken Pharmaceutical, Co., Ltd. Will Pay Astria Therapeutics Up to $32 Million in Upfront and Milestone Payments, Plus Royalties for Japanese Development and Commercialization Rights Related to Navenibart -- --
- 1y agoATXSAstria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in JapanBusiness Wire-- Up to $32 Million in Upfront and Milestone Payments, Plus Royalties -- -- Kaken Expertise in Commercializing Innovative Therapies Supports Navenibart's Potential to be First-Choice HAE Treatment in Japan -- --
- 1y agoATXSAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 180,000 shares of Astria's
- 1y agoATXSAstria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National SummitBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the 2025 US
- 1y agoATXSAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 119,860 shares of Astria's
- 1y agoATXSAstria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation SummitBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in a panel discussion at
- 1y agoATXSAstria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual CongressBusiness Wire-- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction -- -- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction – -- Well-Tolerated with a Favorable Safety Profile -- -- All Patients Remain on
- 1y agoATXSAstria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual CongressBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four posters at the European
- 1y agoATXSAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 62,000 shares of Astria's
- 1y agoATXSAstria Therapeutics to Present at Upcoming Jefferies Global Healthcare ConferenceBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive
- 1y agoATXSAstria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema WorkshopBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the 14th C1 Inhibitor
- 1y agoATXSAstria Therapeutics to Present at Upcoming Eastern Allergy ConferenceBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the Eastern Allergy
- 1y agoATXSAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 33,650 shares of Astria's
- 1y agoATXSAstria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & ImmunologyBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that results from a Phase 1a trial in healthy
- 1y agoATXSAstria Therapeutics to Present at Upcoming Citizens Life Sciences ConferenceBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive
- 1y agoATXSAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 43,650 shares of Astria's
- 1y agoATXSAstria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate UpdateBusiness Wire-- ALPHA-ORBIT Pivotal Phase 3 Trial Evaluating Every 3- and Every 6-Month Administration of Navenibart (STAR-0215) in Hereditary Angioedema is Underway -- -- Initial Efficacy and Safety Data from Navenibart
- 1y agoATXSAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 87,450 shares of Astria's
- 1y agoATXSAstria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary AngioedemaBusiness Wire-- Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on
- 1y agoATXSAstria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care ConferenceBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive
- 1y agoATXSAstria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint CongressBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three posters at the
- 1y agoATXSAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 16,500 shares of Astria's
- 1y agoATXSAstria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences ConferenceBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive
- 1y agoATXSAstria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific SessionBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present quality of life results from
- 1y agoATXSAstria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic DermatitisBusiness Wire-- Early Proof-of-Concept Results from the Phase 1a Trial Anticipated in Q3 2025 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and
- 1y agoATXSAstria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAEBusiness Wire-- Single Pivotal Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period -- -- Pioneering Patient-Centric Dosing Flexibility in HAE with Potential
- 1y agoATXSAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 58,650 shares of Astria's
- 1y agoATXSAstria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAEBusiness Wire-- Navenibart Demonstrated 6 Months of HAE Attack Prevention with 1 or 2 Doses -- -- 90-95% Mean Monthly Attack Rate Reduction Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 67% Attack-Free Rate Over 6 Months
- 1y agoATXSAstria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic DermatitisBusiness Wire-- Phase 1a Trial of STAR-0310 in Healthy Volunteers Expected to Initiate in Q1 2025 -- -- Early Proof-of-Concept Results Expected in Q3 2025 -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company
- 1y agoATXSAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 32,500 shares of Astria's
- 1y agoATXSAstria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateBusiness Wire-- Navenibart (STAR-0215), the Potential Market-Leading Therapy for the Treatment of Hereditary Angioedema, on Track for Expected Phase 3 Initiation in Q1 2025 -- -- Final 3- and 6-Month Results from the ALPHA-STAR
- 1y agoATXSAstria Therapeutics to Present at Upcoming Jefferies London Healthcare ConferenceBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive
- 2y agoATXSAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 210,000 shares of Astria's
- 2y agoATXSAstria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific MeetingBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present interim quality of life
- 2y agoATXSAstria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific MeetingBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters
- 2y agoATXSEuropean Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics' Investigational Therapy for the Treatment of Hereditary AngioedemaBusiness WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that the European Commission (EC) has granted
- 2y agoATXSAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireAstria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 52,000 shares of Astria's